After accounting for differences in disease severity at treatment initiation , this apparent superiority of anakinra over tocilizumab was no longer statistically significant ( propensity score - adjusted hazards ratio 0 . 46 , 95 % confidence interval 0 . 18 - 1 . 20 ) .